EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2762	SAHA	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L2	822196	transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L3	24	L1 same L2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L4	1939	sodium near4 transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L5	11571	hydroxamic	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L6	14211	hydroxam$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L7	0	L4 same L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L8	0	L4 same L5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L9	158756	lung	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L10	767	trichostatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L11	446	L10 and L9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L12	822196	transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L13	1789	hydroxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L14	90233	(asthma or bronchitis or COPD or cystic adj fibrosis)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L15	2	L14 near20 L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L16	2	L14 same L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L17	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L18	1	L4 and L17	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L19	206	L10 and L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L20	0	L10 near 10l23	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L21	75	US-6147224-$.DID. OR US-6124495-$.DID. OR US-6110970-$.DID. OR US-6110955-$.DID. OR US-6110697-$.DID. OR US-6083984-$.DID. OR US-6071923-$.DID. OR US-6068987-$.DID. OR US-6060510-$.DID. OR US-6046237-$.DID. OR US-6043389-$.DID. OR US-6037367-$.DID. OR US-6030993-$.DID. OR US-6004988-$.DID. OR US-6001877-$.DID. OR US-5998654-$.DID. OR US-5986131-$.DID. OR US-5968979-$.DID. OR US-5932606-$.DID. OR US-5910606-$.DID. OR US-5910508-$.DID. OR US-5908868-$.DID. OR US-5891737-$.DID. OR US-5883124-$.DID. OR US-5804601-$.DID. OR US-5795914-$.DID. OR US-5753704-$.DID. OR US-5710178-$.DID. OR US-5705167-$.DID. OR US-5696162-$.DID. OR US-5688819-$.DID. OR US-5677320-$.DID. OR US-5672746-$.DID. OR US-5643949-$.DID. OR US-5607978-$.DID. OR US-5602135-$.DID. OR US-5547988-$.DID. OR US-5541155-$.DID. OR US-5525629-$.DID. OR US-5486540-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L22	45878	hydroxylamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L23	0	L10 near10 L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L24	14309	hydroxam$ or hydroxamide or oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L25	76	US-4564476-$.DID. OR US-4545984-$.DID. OR US-4534979-$.DID. OR US-4505930-$.DID. OR US-4504494-$.DID. OR US-4472430-$.DID. OR US-4440940-$.DID. OR US-4439443-$.DID. OR US-4388459-$.DID. OR US-4371614-$.DID. OR US-4355168-$.DID. OR US-4335054-$.DID. OR US-4309407-$.DID. OR US-4309357-$.DID. OR US-4288253-$.DID. OR US-4258057-$.DID. OR US-4211783-$.DID. OR US-4193931-$.DID. OR US-4188338-$.DID. OR US-4171318-$.DID. OR US-4130653-$.DID. OR US-4127723-$.DID. OR US-4127722-$.DID. OR US-4116975-$.DID. OR US-4113858-$.DID. OR US-4081476-$.DID. OR US-4061656-$.DID. OR US-4048332-$.DID. OR US-4044149-$.DID. OR US-4024182-$.DID. OR US-4011339-$.DID. OR US-3984440-$.DID. OR US-3978100-$.DID. OR US-3909353-$.DID. OR US-3886278-$.DID. OR US-3781314-$.DID. OR US-3755604-$.DID. OR US-3687955-$.DID. OR US-3674884-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L26	8	US-3624127-$.DID. OR US-3551574-$.DID. OR US-3479396-$.DID. OR US-2840586-$.DID. OR US-2680755-$.DID. OR US-6495719-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L27	76	US-5475022-$.DID. OR US-5466718-$.DID. OR US-5420160-$.DID. OR US-5385942-$.DID. OR US-5369108-$.DID. OR US-5320833-$.DID. OR US-5272180-$.DID. OR US-5264424-$.DID. OR US-5246955-$.DID. OR US-5244922-$.DID. OR US-5235068-$.DID. OR US-5141959-$.DID. OR US-5112846-$.DID. OR US-5091569-$.DID. OR US-5089524-$.DID. OR US-5084214-$.DID. OR US-5075330-$.DID. OR US-5064860-$.DID. OR US-5028629-$.DID. OR US-4985436-$.DID. OR US-4981865-$.DID. OR US-4950467-$.DID. OR US-4833257-$.DID. OR US-4820828-$.DID. OR US-4791133-$.DID. OR US-4753934-$.DID. OR US-4731382-$.DID. OR US-4722939-$.DID. OR US-4709076-$.DID. OR US-4699920-$.DID. OR US-4638011-$.DID. OR US-4623661-$.DID. OR US-4621099-$.DID. OR US-4619945-$.DID. OR US-4608390-$.DID. OR US-4607053-$.DID. OR US-4605669-$.DID. OR US-4604407-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L28	2	("20030195257").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/06 05:58
L29	236	L21 or L27 or L25 or L28 or L26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L30	35	L29 and L24	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L31	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L32	0	L4 near10 L31	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L33	2762	SAHA	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L34	2762	l7same L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L35	0	L14 near10 L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L36	12218	lipox$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L37	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L38	51	L14 same L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L39	0	L38 and L36	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L40	0	L38 and L37	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L41	296	L14 and L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L42	3245	L10 or L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L43	205	560/312.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L44	21536	L37 or L36	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L45	24723	L42 or L44	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L46	0	L14 near20 L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L47	767	trichostatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L48	2762	SAHA	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L49	3245	L47 or L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L50	1	L42 same L44	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L51	2	"4731382".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L52	12218	lipox$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L53	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L54	21536	L53 or L52	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L55	11571	hydroxamic	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L56	1939	sodium near4 transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L57	27	L56 and L55	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L58	3	"2002055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L59	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L60	69	L56 and L59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L61	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L62	90233	(asthma or bronchitis or COPD or cystic adj fibrosis)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:06
L63	23	L61 and L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L64	2	"5028629".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L65	26	"0208379"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L66	58	L49 and L54	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L67	0	L62 near20 L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L68	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L69	8	US-3624127-$.DID. OR US-3551574-$.DID. OR US-3479396-$.DID. OR US-2840586-$.DID. OR US-2680755-$.DID. OR US-6495719-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L70	14309	hydroxam$ or hydroxamide or oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L71	2	("20030195257").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/06 05:58
L72	76	US-5475022-$.DID. OR US-5466718-$.DID. OR US-5420160-$.DID. OR US-5385942-$.DID. OR US-5369108-$.DID. OR US-5320833-$.DID. OR US-5272180-$.DID. OR US-5264424-$.DID. OR US-5246955-$.DID. OR US-5244922-$.DID. OR US-5235068-$.DID. OR US-5141959-$.DID. OR US-5112846-$.DID. OR US-5091569-$.DID. OR US-5089524-$.DID. OR US-5084214-$.DID. OR US-5075330-$.DID. OR US-5064860-$.DID. OR US-5028629-$.DID. OR US-4985436-$.DID. OR US-4981865-$.DID. OR US-4950467-$.DID. OR US-4833257-$.DID. OR US-4820828-$.DID. OR US-4791133-$.DID. OR US-4753934-$.DID. OR US-4731382-$.DID. OR US-4722939-$.DID. OR US-4709076-$.DID. OR US-4699920-$.DID. OR US-4638011-$.DID. OR US-4623661-$.DID. OR US-4621099-$.DID. OR US-4619945-$.DID. OR US-4608390-$.DID. OR US-4607053-$.DID. OR US-4605669-$.DID. OR US-4604407-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L73	76	US-4564476-$.DID. OR US-4545984-$.DID. OR US-4534979-$.DID. OR US-4505930-$.DID. OR US-4504494-$.DID. OR US-4472430-$.DID. OR US-4440940-$.DID. OR US-4439443-$.DID. OR US-4388459-$.DID. OR US-4371614-$.DID. OR US-4355168-$.DID. OR US-4335054-$.DID. OR US-4309407-$.DID. OR US-4309357-$.DID. OR US-4288253-$.DID. OR US-4258057-$.DID. OR US-4211783-$.DID. OR US-4193931-$.DID. OR US-4188338-$.DID. OR US-4171318-$.DID. OR US-4130653-$.DID. OR US-4127723-$.DID. OR US-4127722-$.DID. OR US-4116975-$.DID. OR US-4113858-$.DID. OR US-4081476-$.DID. OR US-4061656-$.DID. OR US-4048332-$.DID. OR US-4044149-$.DID. OR US-4024182-$.DID. OR US-4011339-$.DID. OR US-3984440-$.DID. OR US-3978100-$.DID. OR US-3909353-$.DID. OR US-3886278-$.DID. OR US-3781314-$.DID. OR US-3755604-$.DID. OR US-3687955-$.DID. OR US-3674884-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L74	75	US-6147224-$.DID. OR US-6124495-$.DID. OR US-6110970-$.DID. OR US-6110955-$.DID. OR US-6110697-$.DID. OR US-6083984-$.DID. OR US-6071923-$.DID. OR US-6068987-$.DID. OR US-6060510-$.DID. OR US-6046237-$.DID. OR US-6043389-$.DID. OR US-6037367-$.DID. OR US-6030993-$.DID. OR US-6004988-$.DID. OR US-6001877-$.DID. OR US-5998654-$.DID. OR US-5986131-$.DID. OR US-5968979-$.DID. OR US-5932606-$.DID. OR US-5910606-$.DID. OR US-5910508-$.DID. OR US-5908868-$.DID. OR US-5891737-$.DID. OR US-5883124-$.DID. OR US-5804601-$.DID. OR US-5795914-$.DID. OR US-5753704-$.DID. OR US-5710178-$.DID. OR US-5705167-$.DID. OR US-5696162-$.DID. OR US-5688819-$.DID. OR US-5677320-$.DID. OR US-5672746-$.DID. OR US-5643949-$.DID. OR US-5607978-$.DID. OR US-5602135-$.DID. OR US-5547988-$.DID. OR US-5541155-$.DID. OR US-5525629-$.DID. OR US-5486540-$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L75	236	L74 or L72 or L73 or L71 or L69	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L76	35	L75 and L70	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L77	1	L49 same L54	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L78	175	oxamflatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L79	1789	hydroxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L80	822196	transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L81	296	L62 and L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L82	2	L62 same L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L83	14211	hydroxam$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L84	0	L56 same L83	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L85	24723	L49 or L54	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L86	205	560/312.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L87	206	L47 and L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L88	0	L47 near10 L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L89	0	L56 same L55	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L90	0	L62 near10 L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L91	0	L47 near 10l23	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L92	51	L62 same L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L93	0	L92 and L53	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L94	1	L56 and L86	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L95	158756	lung	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L96	446	L47 and L95	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L97	2762	l7same L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L98	0	L92 and L52	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L99	2	L62 near20 L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L100	1	L56 and L68	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L101	45878	hydroxylamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L102	0	L56 near10 L59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L103	1	L4 and L43	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L104	33	L4 and L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L105	2	L4 same L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L106	17	L17 and L12	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L107	27	L4 and L5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L108	39	L10 same L9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L109	2	"5534654" .pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L110	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L111	23	L110 and L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L112	21	L14 same L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L113	8	L10 same L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L114	3	L14 near10 L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L115	3	"2002055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L116	2	L14 near10 L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L117	69	L4 and L31	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L118	4	L14 near20 L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L119	2	"20020055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L120	26	"0208379"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L121	5	L4 same L31	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L122	21	L14 and L30	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

EAST Search History

L123	2	"4731382".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L124	2	"5028629".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L125	58	L42 and L44	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L126	2	L56 same L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L127	17	L68 and L80	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L128	2	"5534654" .pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L129	8	L47 same L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L130	21	L62 same L101	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L131	21	L62 and L76	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L132	2	L62 near10 L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L133	4	L62 near20 L101	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L134	2	"20020055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59

EAST Search History

L135	5	L56 same L59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L136	33	L56 and L83	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L137	3	L62 near10 L101	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L138	39	L47 same L95	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L139	259	L14 and L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L140	175	oxamflatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L141	259	L62 and L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L142	79	L1 same L9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L143	77	l5 same l53	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 06:11
L144	201383	lung or asthma	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 06:59
L145	70	l143 and l144	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 06:11
L146	8242	COPD	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 07:00

EAST Search History

L147	222	l37 same l146	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 07:00
L148	15	l37 near10 l146	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 10:45
L149	548	(514/575).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/06 10:46
L150	148	l62 and l149	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:00
L151	5	"9912899"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:00
L152	7	((asthma or bronchitis or COPD or cystic adj fibrosis) and (SAHA or trichostatin)).clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:07

NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/CAplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/CAplus enhanced with utility model patents from China
NEWS 27 JUL 16 CAplus enhanced with French and German abstracts
NEWS 28 JUL 18 CA/CAplus patent coverage enhanced
NEWS 29 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 30 JUL 30 USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 3 Aug 2007 (20070803/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> copd and asthma and (cystic fibrosis) and bronchitis
          3342 COPD
            17 COPDS
          3356 COPD
                 (COPD OR COPDS)
         35881 ASTHMA
            22 ASTHMAS
         35889 ASTHMA
                 (ASTHMA OR ASTHMAS)
         16731 CYSTIC
             1 CYSTICS
         16732 CYSTIC
                 (CYSTIC OR CYSTICS)
         38199 FIBROSIS
             1 FIBROSISES
         38199 FIBROSIS
                 (FIBROSIS OR FIBROSISES)
         12689 CYSTIC FIBROSIS
                 (CYSTIC(W)FIBROSIS)
          6450 BRONCHITIS
             1 BRONCHITISES
          6451 BRONCHITIS
                 (BRONCHITIS OR BRONCHITISES)
L1          35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS

=> lipoxygenase or leukotriene
         17728 LIPOXYGENASE
          1535 LIPOXYGENASES
         17969 LIPOXYGENASE
                 (LIPOXYGENASE OR LIPOXYGENASES)
         14523 LEUKOTRIENE
          8056 LEUKOTRIENES
         16744 LEUKOTRIENE
                 (LEUKOTRIENE OR LEUKOTRIENES)
L2       30339 LIPOXYGENASE OR LEUKOTRIENE

=> l1 and l2
L3          10 L1 AND L2

=> d l3 5-10 ti

L3   ANSWER 5 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Treatment of respiratory and lung diseases with antisense oligonucleotides
     and a bronchodilating agent

L3   ANSWER 6 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Treatment of respiratory and lung diseases with antisense oligonucleotides
     and a bronchodilating agent

L3   ANSWER 7 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl- acid
     amide derivatives as inhibitors of phosphodiesterase IV isozymes

L3   ANSWER 8 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4
     isozymes

L3   ANSWER 9 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   LTB4 antagonism
```

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders

=> diene
69783 DIENE
24296 DIENES
L4 82863 DIENE
(DIENE OR DIENES)

=> l3 and l4
L5 0 L3 AND L4

=> l2 and l4
L6 226 L2 AND L4

=> d l3 8-10 ti fbib abs

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes
AN 2002:594822 CAPLUS
DN 137:154857
TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes
IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002060875	A1	20020808	WO 2001-IB2341		20011206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-265492P	P	20010131
	CA 2436535	A1	20020808	CA 2001-2436535		20011206
				US 2001-265492P	P	20010131
				WO 2001-IB2341	W	20011206
	AU 2002220966	A1	20020812	AU 2002-220966		20011206
				US 2001-265492P	P	20010131
				WO 2001-IB2341	W	20011206
	EP 1355884	A1	20031029	EP 2001-273556		20011206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-265492P	P	20010131
				WO 2001-IB2341	W	20011206
	EE 200300360	A	20031215	EE 2003-360		20011206
				US 2001-265492P	P	20010131
				WO 2001-IB2341	W	20011206
	BR 2001016852	A	20040225	BR 2001-16852		20011206
				US 2001-265492P	P	20010131
				WO 2001-IB2341	W	20011206

HU 200400637	A2	20040628	HU 2004-637		20011206
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
JP 2004520386	T	20040708	JP 2002-561026		20011206
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
CN 1518542	A	20040804	CN 2001-823071		20011206
			US 2001-265492P	P	20010131
NZ 526453	A	20050128	NZ 2001-526453		20011206
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
US 2002193612	A1	20021219	US 2002-62813		20020131
US 6649633	B2	20031118			
			US 2001-265492P	P	20010131
IN 2003MN00608	A	20050318	IN 2003-MN608		20030617
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
ZA 2003004894	A	20040624	ZA 2003-4894		20030624
			US 2001-265492P	P	20010131
US 2004048903	A1	20040311	US 2003-613988		20030702
US 6953810	B2	20051011			
			US 2001-265492P	P	20010131
			US 2002-62813	A3	20020131
BG 108038	A	20040730	BG 2003-108038		20030728
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
NO 2003003397	A	20030919	NO 2003-3397		20030730
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
MX 2003PA06887	A	20031113	MX 2003-PA6887		20030730
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206

OS MARPAT 137:154857
GI



I



II

AB The title compds. [I; g = 0-1; j = 0-1; provided that when j = 0, n must be 2; k = 0-1; m = 0-2; n = 1-2; W1 = O, SOt (t = 0-2), NR3; W2 = OCR9R10, or absent; Y = CR1, NOk (k = 0-1); R9, R10 = H, F, CF3, etc.; or R9 and R10 are taken together, but only in the case where m = 1, to form a spiro moiety; R7, R8 have the same meaning as R9, R10 except that one of them must be H; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, Ph, etc.; R4-R6 = H, F, Cl, etc.; Q1 = Ph, benzodioxyl, etc.; Q2 = biaryl moiety], useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepared E.g., a multi-step synthesis of the amide II, starting from Me 3-bromobenzoate and 4-formylbenzeneboronic acid, was given. Compds. I showed anti-inflammatory activity at 0.0001 μM to 20.0 μM in whole blood assay for LTE4.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI LTB4 antagonism
AN 2001:360988 CAPLUS
DN 136:47743
TI LTB4 antagonism
AU Jennewein, H. M.; Anderskewitz, R.; Meade, C. J.; Pairet, M.; Birke, F.
CS Department of Pulmonary Research, Boehringer Ingelheim KG, Ingelheim, Germany
SO Progress in Respiratory Research (2001), 31(New Drugs for Asthma, Allergy and COPD), 121-125
CODEN: PRRRAE; ISSN: 1422-2140
PB S. Karger AG
DT Journal; General Review
LA English
AB A review is given. LTB4 is one of the most important mediators for neutrophil granulocyte survival, trafficking, and activation. A major

role was proposed in the pathophysiol. of respiratory diseases characterized by a neutrophilic-type of inflammation, such as chronic bronchitis, severe asthma, and cystic fibrosis. Elevated LTB4 levels were found in sputum and BAL fluid of patients with COPD, cystic fibrosis, and severe asthma. This constitutes the medical rationale for testing LTB4 antagonists in certain forms of asthma and in COPD. A 1st clin. trial has demonstrated that an LTB4 antagonist could reduce the number of BAL fluid neutrophils in patients with mild asthma. Several LTB4 antagonists are known, the most important ones being CP 195543, SC 53228, CGS 25019C, ONO 4057, LY 293111 Na, and BIIL 284 BS. All these compds. are specific LTB4 antagonists, but they differ with respect to efficacy and pharmacokinetic properties. Their clin. evaluation is ongoing.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders
AN 2000:133697 CAPLUS
DN 132:203144
TI Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders
IN Nyce, Jonathan W.
PA East Carolina University, USA
SO PCT Int. Appl., 1343 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2000009525	A2	20000224	WO 1999-US17712		19990803
	WO 2000009525	A3	20000518			
	W: AU, CA, CN, MX, RU, US					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
				US 1998-95212P	P	19980803
	CA 2333901	A1	20000224	CA 1999-2333901		19990803
				US 1998-95212P	P	19980803
				WO 1999-US17712	W	19990803
	AU 9953374	A1	20000306	AU 1999-53374		19990803
				US 1998-95212P	P	19980803
				WO 1999-US17712	W	19990803
	EP 1102786	A2	20010530	EP 1999-939006		19990803
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
				US 1998-95212P	P	19980803
				WO 1999-US17712	W	19990803

OS MARPAT 132:203144
AB A composition comprises a nucleic acid comprising an oligo antisense to a target such as polypeptide(s) associated with an ailment afflicting lung airways, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixts. Various formulations contain a requisite carrier, and optionally other additives and biol. active agents. The agent of the invention may be prepared by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) associated with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60% free of thymidine (T) and synthesizing one or more antisense oligonucleotide(s) to the mRNA segments

which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepared by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the antisense oligonucleotides with a universal base. The agent, composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, allergy(ies) and/or inflammation, such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, pulmonary hypertension and bronchoconstriction, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), ischemic conditions including ischemia itself, and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastasis, etc., as well as all types of cancers with may metastasize or have metastasized to the lung(s), including breast and prostate cancer. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. The present agent is effectively administered preventatively, prophylactically or therapeutically by itself for conditions without known therapies, or as a substitute for, or in conjunction with, other therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject, so that the agent has direct access to the airways and the lungs. The invention is exemplified with specificity and pharmacokinetic studies using phosphorothioated antisense oligonucleotides targeted to the adenosine receptors A1, A2a, A2b, and A3.

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.84	31.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:08:38 ON 06 AUG 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:51:40 ON 06 AUG 2007
FILE 'CAPLUS' ENTERED AT 10:51:40 ON 06 AUG 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.84	31.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -2.34 -2.34

=> d his

(FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007)

FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007
L1 35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS
L2 30339 LIPOXYGENASE OR LEUKOTRIENE
L3 10 L1 AND L2
L4 82863 DIENE
L5 0 L3 AND L4
L6 226 L2 AND L4

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.84	31.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'REGISTRY' ENTERED AT 10:51:56 ON 06 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6
DICTIONARY FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10715377\10715377 saturated lniker.str





chain nodes :
7 8 9 10 11
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-8 8-9 8-11 9-10

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
8-9 8-11
exact bonds :
5-7 7-8 9-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l7 sss sam
SAMPLE SEARCH INITIATED 10:52:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 344 TO ITERATE

100.0% PROCESSED 344 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5768 TO 7992
PROJECTED ANSWERS: 1520 TO 2760

L8 50 SEA SSS SAM L7

=> dscan
0 DSCAN
L9 0 DSCAN

=> d scan l7
L7 HAS NO ANSWERS

=> d scan l8

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanediamide, N1-[(1S)-1-[[4-[[(iminophenylmethyl)amino]methyl]phenyl]methyl]-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-3-(3-phenylpropyl)-, monohydrochloride, (2R,3S)- (9CI)

MF C42 H51 N5 O4 . Cl H

Absolute stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[[3-(diethylamino)propyl]sulfonyl]-2-(2-methylpropyl)hydrazide, (2R,3S,5E)- (9CI)
MF C28 H48 N4 O5 S
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Pyrrolidinebutanamide, β-[3-[3,5-bis(trifluoromethyl)phenyl]propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (9CI)
MF C19 H22 F6 N2 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanediamide, N1-[(1S)-1-[[(1,1-diphenylethyl)amino]carbonyl]-2,2-dimethylpropyl]-N4-hydroxy-2-(3-phenylpropyl)-, (2R)- (9CI)
MF C33 H41 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,2,3-Triazole-1-acetic acid, 2-[(2R,3S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-1-[(2S)-2-methylbutyl]hydrazide (9CI)
MF C26 H40 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[(2S)-2,4-diamino-1,4-dioxobutyl]-2-(2-methylpropyl)hydrazide, (2R,3S,5E)- (9CI)
MF C25 H39 N5 O5
CI COM

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenehexanamide, ε-hydroxy-N-(1-methoxy-1-methylethoxy)-4-[[4-(methylthio)phenyl]ethynyl]-, (εR)- (9CI)
MF C25 H31 N O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Octenamide, N-hydroxy-8-(2-naphthalenyl)-
MF C18 H21 N O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-hexanamide, 4'-chloro-N,ε-dihydroxy-ε-(3-methoxy-1-propynyl)- (9CI)
MF C22 H24 Cl N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Phenylalanine, N-[(2S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-4-[[(1-iminoethyl)amino]methyl]-, methyl ester (9CI)
MF C30 H42 N4 O5
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Thiomorpholinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (9CI)
MF C19 H28 N2 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.85	36.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

FILE 'CAPLUS' ENTERED AT 10:53:20 ON 06 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 5 Aug 2007 (20070805/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> l8
L10          26 L8

=> d his

     (FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007)

     FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007
L1           35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS
L2        30339 LIPOXYGENASE OR LEUKOTRIENE
L3           10 L1 AND L2
L4        82863 DIENE
L5            0 L3 AND L4
L6          226 L2 AND L4

     FILE 'REGISTRY' ENTERED AT 10:51:56 ON 06 AUG 2007
L7                STRUCTURE UPLOADED
L8           50 SEARCH L7 SSS SAM
L9            0 DSCAN

     FILE 'CAPLUS' ENTERED AT 10:53:20 ON 06 AUG 2007
L10          26 L8

=> l2 and l10
L11           0 L2 AND L10

=> l1 and l11
L12           0 L1 AND L11

=> l1 and l10
L13           0 L1 AND L10

=> logoff hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
FULL ESTIMATED COST                               0.94       37.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY     SESSION
CA SUBSCRIBER PRICE                               0.00       -2.34

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:54:22 ON 06 AUG 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x
```

```
LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:55:32 ON 06 AUG 2007
FILE 'CAPLUS' ENTERED AT 10:55:32 ON 06 AUG 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.94      37.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -2.34

=> prostaglandin
         71302 PROSTAGLANDIN
         44741 PROSTAGLANDINS
L14      82054 PROSTAGLANDIN
                (PROSTAGLANDIN OR PROSTAGLANDINS)

=> d his

     (FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007)

     FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007
L1           35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS
L2        30339 LIPOXYGENASE OR LEUKOTRIENE
L3           10 L1 AND L2
L4        82863 DIENE
L5            0 L3 AND L4
L6          226 L2 AND L4

     FILE 'REGISTRY' ENTERED AT 10:51:56 ON 06 AUG 2007
L7               STRUCTURE UPLOADED
L8           50 SEARCH L7 SSS SAM
L9            0 DSCAN

     FILE 'CAPLUS' ENTERED AT 10:53:20 ON 06 AUG 2007
L10          26 L8
L11           0 L2 AND L10
L12           0 L1 AND L11
L13           0 L1 AND L10
L14       82054 PROSTAGLANDIN

=> hydroxamic
          7264 HYDROXAMIC
             1 HYDROXAMICS
L15       7265 HYDROXAMIC
                (HYDROXAMIC OR HYDROXAMICS)

=> l14(l)l15
L16          10 L14(L)L15

=> d l16 1-10 ti

L16  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Parallel synthesis and in vitro activity of novel anthranilic
     hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase
     activity

L16  ANSWER 2 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its
     Target Genes Including COX-2
```

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Design, parallel chemical synthesis and in vitro characterization of novel hydroxamate-based prostaglandin H2 synthase inhibitors

L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI A process for the preparation of prostaglandin F analogs

L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities

L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and formulation of 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs useful in treatment of thrombotic disease

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Nonsteroidal antiinflammatory compounds to treat inflammation

L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI A new class of irreversible inhibitors of leukotriene biosynthesis

L16 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Hydroxamic acid derivatives of prostaglandins

=> d l16 10 ti fbib abs

L16 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Hydroxamic acid derivatives of prostaglandins
AN 1977:189308 CAPLUS
DN 86:189308
TI Hydroxamic acid derivatives of prostaglandins
IN Aries, Robert
PA Fr.
SO Fr. Demande, 6 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2290425	A1	19760604	FR 1974-36785	19741106
	FR 2290425	B3	19770805		
				FR 1974-36785 A	19741106

GI



I

AB PGF2 alkyl esters were treated with HONH2.HCl and Na alkoxides to give PGF hydroxamic acids I (R = OH, R1 = H) and I (R = H, R1 = OH).

=> d l16 1-9 ti fbib abs

L16 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity
AN 2005:1071789 CAPLUS
DN 144:22699
TI Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity
AU Lee, Jean; Chubb, Anthony J.; Moman, Edelmiro; McLoughlin, Brian M.; Sharkey, Caroline T.; Kelly, John G.; Nolan, Kevin B.; Devocelle, Marc; Fitzgerald, Desmond J.
CS Centre for Synthesis and Chemical Biology, Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, Dublin, 2, Ire.
SO Organic & Biomolecular Chemistry (2005), 3(20), 3678-3685
CODEN: OBCRAK; ISSN: 1477-0520
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 144:22699
AB Currently available non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin are directed at the cyclooxygenase (COX) site, but not the peroxidase (POX) activity of prostaglandin H2 synthase (PGHS). They are thus unable to inhibit the free-radical induced tissue injury associated with PGHS peroxidase activity, which can occur independently of the COX site. A lead compound, anthranilohydroxamic acid (AHA) was found to have significant PGHS-POX inhibitory activity (IC50 = 72 μM). To define the critical parameters for PGHS-POX inhibition, 29 AHA derivs., synthesized from their acid precursors, using solid phase synthesis, were investigated. In vitro anal. demonstrated a ten-fold improvement in inhibition with 3,5-diiodoanthranilohydroxamic acid (IC50 = 7 μM).
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2
AN 2005:1011798 CAPLUS
DN 143:278693
TI Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2
AU Yamaguchi, Kentaro; Lantowski, Agnieszka; Dannenberg, Andrew J.; Subbaramaiah, Kotha
CS Department of Medicine, Weill Medical College of Cornell University, New York, NY, 10021, USA
SO Journal of Biological Chemistry (2005), 280(38), 32569-32577
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB Cyclooxygenase-2 (COX-2) is considered to be a target for anticancer therapy. Histone deacetylase (HDAC) inhibitors exhibit antitumor activity, but the mechanisms of action are incompletely understood. The authors investigated whether HDAC inhibitors blocked AP-1-mediated activation of COX-2 transcription. Trichostatin A and suberoylanilide hydroxamic acid, two structurally related inhibitors of HDAC activity, blocked AP-1-mediated induction of COX-2 expression and prostaglandin E2 biosynthesis. Chromatin immunopptn. assays

indicated that HDAC inhibitors suppressed c-Jun binding to the COX-2 promoter and thereby blocked transcription. The observed reduction in binding reflected reduced levels of c-Jun. HDAC inhibitors suppressed the induction of c-jun transcription by blocking the recruitment of the preinitiation complex (RNA polymerase II and TFIIB) to the c-jun promoter. HDAC3 but not HDAC1 or HDAC2 was required for AP-1-mediated stimulation of c-jun expression. Because HDAC inhibitors suppressed the induction of c-jun gene expression, resulting in reduced COX-2 transcription, it was important to determine whether other known AP-1 target genes were also modulated. Cyclin D1 and collagenase-1 are AP-1-dependent genes that have been implicated in carcinogenesis. HDAC inhibitors suppressed the induction of both cyclin D1 and collagenase-1 transcription by inhibiting the binding of c-Jun to the resp. promoters. Taken together, these results suggest that HDAC inhibitors block the induction of c-jun transcription by inhibiting the recruitment of the preinitiation complex to the c-jun promoter. This led, in turn, to reduced expression of several activator protein-1-dependent genes (COX-2, cyclin D1, collagenase-1). These findings provide new insights into the mechanisms underlying the antitumor activity of HDAC inhibitors.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Design, parallel chemical synthesis and in vitro characterization of novel hydroxamate-based prostaglandin H2 synthase inhibitors
AN 2005:739805 CAPLUS
TI Design, parallel chemical synthesis and in vitro characterization of novel hydroxamate-based prostaglandin H2 synthase inhibitors
AU Lee, Jean
CS Department of Pharmaceutical and Medicinal Chemistry, Department of Pharmacy, Centre for Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, Dublin, N/A, Ire.
SO Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-294 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69HFCL
DT Conference; Meeting Abstract; (computer optical disk)
LA English
AB Prostaglandin H2 synthase (PGHS), the first enzyme in the biotransformation of arachidonic acid to prostaglandins, has two active sites, a cyclooxygenase (COX), the target of aspirin, and a spatially and functionally distinct peroxidase (POX). The POX activity is independent of the COX activity, however the reverse does not hold. Inhibitors of the POX activity are of potential therapeutic value as unchecked peroxidase activity, leading to free radicals, contribute to disease progression despite NSAID administration. Aspirin irreversibly inhibits COX by acetylating a serine residue in the active site. Recently, we have produced a series of acetylating compds., including triacetylsalicylhydroxamic acid (TriACSHA), a more potent irreversible acetylating agent than aspirin and based on a salicylhydroxamic acid scaffold. Similarly, recent work carried out in our labs. has shown that anthranilic hydroxamic acid (AHA) is able to inhibit the peroxidase activity of PGHS. The presence of the hydroxamic acid group is essential as the carboxylic analog has a significant reduced inhibitory activity. A library of 30 AHA derivs., displaying various substituents on the aromatic ring, was synthesized by parallel synthesis. Four potent peroxidase inhibitors with IC50's in the low μM range have been identified. Structure-Activity Relationships are being investigated, looking at the other randomisation points on this AHA core scaffold.

L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2
AN 2004:819373 CAPLUS
DN 142:19059

TI Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2
AU Ouellet, Marc; Aitken, Susan M.; English, Ann M.; Percival, M. David
CS Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, QC, H9R 4P8, Can.
SO Archives of Biochemistry and Biophysics (2004), 431(1), 107-118
CODEN: ABBIA4; ISSN: 0003-9861
PB Elsevier
DT Journal
LA English
AB The cyclooxygenase activity of the bifunctional enzyme prostaglandin H2 synthase-2 (PGHS-2) is the target of non-steroidal anti-inflammatory drugs: Inhibition of the peroxidase activity of PGHS has been less studied. Using Soret absorption changes, the binding of aromatic hydroxamic acids to the peroxidase site of PGHS-2 was examined to investigate the structural determinants of inhibition. Typical of mammalian peroxidases, the Kd for benzhydroxamic acid (42 mM) is much greater than that for salicylhydroxamic acid (475 μM). Binding of the hydroxamic acid tepoxalin (25 μM) resulted in only minor Soret changes. However, tepoxalin is an efficient reducing co-substrate, indicating that it is an alternative electron donor rather than an inhibitor of the peroxidase activity. Aromatic hydrazides are metabolically activated inhibitors of peroxidases. 2-Naphthoic hydrazide (2-NZH) caused the time- and concentration-dependent inhibition of both PGHS-2 peroxidase and cyclooxygenase activities. H2O2 was required for the inactivation of both PGHS-2 activities and indomethacin (which binds at the cyclooxygenase site) did not affect the peroxidase inhibitory potency of 2-NZH. A series of aromatic hydrazides were found to be potent inhibitors of PGHS-2 peroxidase activity with IC50 values in the 6-100 μM range for 13 of the 18 hydrazides examined Selective inhibition of PGHS-2 over myeloperoxidase and horseradish peroxidase isoenzyme C was increased by certain ring substitutions. In particular, a chloro group para to the hydrazide moiety increased the PGHS-2 selectivity relative to both myeloperoxidase and horseradish peroxidase isoenzyme C.
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI A process for the preparation of prostaglandin F analogs
AN 1999:194119 CAPLUS
DN 130:252191
TI A process for the preparation of prostaglandin F analogs
IN Amburgey, Jack S., Jr.; Wos, John August; Delong, Mitchell Anthony; De, Biswanath; Dai, Haiyan George; Soper, David Lindsey
PA The Procter & Gamble Company, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9912899	A1	19990318	WO 1998-US18595	19980904
W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1997-58253P	P 19970909
AU 9893058	A	19990329	AU 1998-93058	19980904
			US 1997-58253P	P 19970909

				WO 1998-US18595	W 19980904
	ZA 9808416	A	20000322	ZA 1998-8416	19980915
				WO 1998-US18595	W 19980904

OS CASREACT 130:252191; MARPAT 130:252191
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing title compds. I (R1 = CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)R5, or tetrazole where R5 = alkyl, heteroalkyl, carbocyclic or heterocyclic aliphatic ring, aromatic or heteroarom.
ring; R2 = H, alkyl; each R3 is independently H, alkyl, alkoxy, haloalkyl, carbocyclic or heterocyclic aliphatic ring, aromatic or heteroarom. ring; Y = NR4, S, S(O), S(O2), O or a bond provided that no carbon has more than one heteroatom attached to it, characterized in that R4 = H, alkyl, acyl; p is from 0-5, q is from 0-5, and p + q is from 0-5 provided when Y is a bond p is at least 1; Z = H, Me, carbocyclic or heterocyclic aliphatic ring, aromatic or heteroarom. ring, provided when Y is S, S(O) or S(O)2 Z is not H) was accomplished via intermediates II (R6 = carboxylic acid, carboxylic acid ester, comprising a saturated or unsatd. C1-C8 alkyl, a carbocyclic ring, a hydroxamic acid, hydroxymethyl, sulfonic acid, sulfonyl ester, sulfonyl amide and tetrazole; the two R7 form a 5- or 6-membered monocyclic aliphatic oxaheterocycle or a 8 to 12 member bicyclic aliphatic heterocycle), or a salt or protected form thereof. The preparation of II comprises (a) reacting a Corey aldehyde with an activated diol or two equivalent of an activated monohydric alc. to form an acetal; (b) deprotection, of the acetal deriv of step (a) to form a hydroxy acetal; (c) optionally reprotecting the hydroxy acetal of step (b); (d) reducing (b) or (c) to provide a lactol derivative; and (e) condensing the lactol derivative of step (d) with a phosphonium salt to form the intermediate acetal . Thus tetranor prostaglandin F1α III was prepared in 8 steps from Corey aldehyde IV via the acetal intermediate V.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities
AN 1995:628939 CAPLUS
DN 123:102272
TI Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities
AU Tam, Susanna S. C.; Lee, Daniel H. S.; Wang, Elizabeth Y.; Munroe, Donald G.; Lau, Catherine Y.
CS Discovery Res., R. W. Johnson Pharmaceutical Res. Inst., Don Mills, ON, M3C 1L9, Can.
SO Journal of Biological Chemistry (1995), 270(23), 13948-55
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB Prostaglandin-H synthase-1, the rate-limiting enzyme in prostaglandin synthesis, has both cyclooxygenase (CO) and peroxidase (PO) activities. While most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit only the CO activity, the authors describe an inhibitor, tepoxalin, that inhibits both the CO (IC50 = 0.1 μM) and the PO (IC50 = 4 μM) activities. Unlike many NSAIDs which are competitive inhibitors of CO, tepoxalin is a noncompetitive inhibitor of CO and its inhibitory effect on PO but not CO is reversed by excess heme. Moreover, inhibition of the PO activity by tepoxalin is not dependent on the enzymic turnover of the CO activity. The hydroxamic acid of tepoxalin

is responsible for the PO inhibition since a carboxylic acid derivative of tepoxalin retains full CO but not PO inhibition. The authors postulated that the hydroxamic group might confer the ability to inhibit PO on conventional CO inhibitors. This idea was supported by the observation that naproxen hydroxamic acid, but not naproxen showed PO inhibition. Furthermore, tepoxalin's carboxylic acid analog and naproxen each competitively relieved PO inhibition by their resp. hydroxamic acids. The intracellular activity of PO as monitored by the release of reactive oxygen species was also inhibited by both tepoxalin and naproxen hydroxamic acid. These observations suggest a strategy for the design of novel compds. to inhibit prostaglandin synthase PO. The therapeutic implications of these novel PO inhibitors are discussed.

L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and formulation of 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs useful in treatment of thrombotic disease
AN 1988:492638 CAPLUS
DN 109:92638
TI Preparation and formulation of 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs useful in treatment of thrombotic disease
IN Nakane, Masami; Reid, Joyce
PA E. R. Squibb and Sons, Inc., USA
SO U.S., 19 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 4734425	A	19880329	US 1986-920006		19861017
	GB 2196338	A	19880427	GB 1987-22764		19870928
	GB 2196338	B	19900808			
				US 1986-920006	A	19861017
	FR 2605319	A1	19880422	FR 1987-13867		19871007
	FR 2605319	B1	19891222			
				US 1986-920006	A	19861017
	DE 3735128	A1	19880421	DE 1987-3735128		19871016
				US 1986-920006	A	19861017
	JP 63104981	A	19880510	JP 1987-262559		19871017
				US 1986-920006	A	19861017

OS CASREACT 109:92638; MARPAT 109:92638
GI



I

AB Title compds. I (A = CH:CH, CH2CH2; M = 1-5; R = HO2C, CO2alkyl, CO2 alkali metal, CO2polyhydroxyamine salt, HOCH2, tetrazolyl, R4R5NCO, R4, R5 = H, alkyl, HO, alkoxy, aryl, at least 1 of R4 and R5 being other than HO or alkoxy; R1, R2 = H, HO, provided that 1 of R1 is HO, the other is H; o = 1-12, R3 = H, alkyl, alkenyl, arylamine, etc.), their salts and stereoisomers, which are cardiovascular agents useful, e.g., in treatment of thrombotic disease (no data) were prepared Me [1S-[1α,2β(5Z),3β,4α]]-7-[(3-(aminomethyl)-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoate prepared in 5 steps from hydroxylamine O-tetrahydropyran ether and Me(CH2)5CON(OH)CH2CO2H dissolved

in THF in Ar atmospheric was treated with DCC to give [1S-[1α,2β(5Z),3β,4α]]-I (A = CH:CH; n = 3; R = MeO2C; R1 = HO; q = 1; R2 = H; R3 = Me(CH2)4).

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI Nonsteroidal antiinflammatory compounds to treat inflammation
AN 1986:400628 CAPLUS
DN 105:628
TI Nonsteroidal antiinflammatory compounds to treat inflammation
IN Smerbeck, Richard V.; Pittz, Eugene P.
PA Warner-Lambert Co., USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4559328	A	19851217	US 1984-623271	19840621
	CA 1241919	A1	19880913	CA 1985-479481	19850418
				US 1984-623271 A	19840621

OS MARPAT 105:628
GI



I

AB Antiinflammatory agents I (R1 = OMe, CH2OH, CO2H, Ph, OH, hydroxamic acid; R2 = H, OH, SH; R3 = H, OH) are useful for the treatment of inflammation on mammals. Skin inflammation from UVB irradiation of guinea pigs showed severe blanching (blanching score 3) 1 h after topical application of p-hydroxydiphenyl (10 μL of 3% solution in 90% DMSO as compared with moderate blanching (blanching score 2) with a 3% 2-hydroxybenzophenone control solution Thus, the compds. inhibited prostaglandin production as indicated by the reduction of inflammation evidenced by blanching.

L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
TI A new class of irreversible inhibitors of leukotriene biosynthesis
AN 1985:108686 CAPLUS
DN 102:108686
TI A new class of irreversible inhibitors of leukotriene biosynthesis
AU Corey, E. J.; Cashman, John R.; Eckrich, Thomas M.; Corey, David R.
CS Dep. Chem., Harvard Univ., Cambridge, MA, 02138, USA
SO Journal of the American Chemical Society (1985), 107(3), 713-15
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
GI



I



II



III, X=OH

IV, X=NH_2

AB 7-Thiaarachidonic acid (I) and 3 truncated analogs (II, III, and IV) were synthesized by a stereospecific method, along with the sulfoxides of I-III and the hydroxamic acid of III. I-IV were potent irreversible inhibitors of the 1st step in leukotriene biosynthesis, the conversion of arachidonate to 5-HPETE by the 5-lipoxygenase (5-LO) from RBL-1 cells in the presence of air. The rate consts. for the aerobic 5-LO deactivation by I-IV (min-1 at 30°) were 0.63, 0.50, 0.43, and 0.39, resp. The sulfoxides of I-III were strictly competitive inhibitors of 5-LO. The 7-thia acids, I-III, were reversible, competitive inhibitors of the prostaglandin synthetase (arachidonate cyclooxygenase) from ram seminal vesicles. A mechanistic working hypothesis which accommodates the present facts on 5-LO is presented. The 7-thia-5,8(Z)-dienoic acids are exceptionally interesting for physiol. and therapeutic studies.

```
=> logtofdf hold
          0 LOGTOFDF
      42949 HOLD
      29154 HOLDS
      70995 HOLD
                (HOLD OR HOLDS)
L17       0 LOGTOFDF HOLD
                (LOGTOFDF(W)HOLD)

=> logoff hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               45.85      82.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -7.80     -10.14

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:02:22 ON 06 AUG 2007
```